Dear Customer,

Philips has become aware of a potential safety issue with SmartPerfusion and 2D Perfusion, where the information provided by these software products might not be accurate.

SmartPerfusion and 2D Perfusion assist in the diagnosis of perfusion alterations of tissues, based on digital subtraction angiography (DSA), by providing color-coded images generated from the DSA series. It can visualize multiple functional parameters related to the time density function. It also provides a comparison between pre-, peri-, and post-procedural color-coded images.

Clinical diagnosis or treatment is not to be based on SmartPerfusion or 2D Perfusion results only. All findings, decisions, and diagnoses must be confirmed by the use of DSA.

This URGENT Field Safety Notice is intended to inform you about:

1. What the problem is and under what circumstances it can occur

Philips has identified through an internal investigation that SmartPerfusion and 2D Perfusion have technical issues related to the way the perfusion signal is generated and processed, which may lead to inaccurate presentations of Time Density Curves and images.

No adverse events related to this issue have been reported to Philips as of 20 February 2023.
2. Hazard/harm associated with the issue

The identified issue may result in inaccurate presentations during clinical use, and/or poor image quality. When based on SmartPerfusion or 20 Perfusion only, subsequent clinical decisions could potentially result in overtreatment or undertreatment of patients in the Cathlab for peripheral artery disease (PAD).

3. Affected products and how to identify them

All software releases of SmartPerfusion and 20 Perfusion are affected by this issue. SmartPerfusion and 20 Perfusion are installed on the Interventional Workspot of the Philips Allura Exper or Azurion systems.

To identify if the SmartPerfusion or 20 Perfusion software is available in your system, please follow the following steps on the Interventional Workspot:

Pic 1: On Interventional Tools Workspot, in the patient list screen, click on help (see red box and arrow)

Pic 2: In the about box click on EULA (see red box and arrow)
Pic 3: Check if SmartPerfusion or 2D Perfusion license is available on the system (see red box and arrow)

- **SmartPerfusion:**

- **2D Perfusion:**

4. Actions that should be taken by the customer / user in order to prevent risks for patients or users

- Stop using SmartPerfusion and 2D Perfusion.
  - NOTE: This message does not impact (ether parts of) the Philips Allura Xper or Azurion Systems or ether tools within the Interventional Workspot. The Philips Allura Xper and Azurion Systems as welt as ether Interventional Workspot tools may continue to be used.

- Place this Urgent Field Safety Notice with the documentation of the System.

- Circulate this notice to all users so that they are aware of the product issue.

- Return the attached reply form to Philips to confirm that the users of the System have reviewed and understood this Urgent Field Safety Notice.
5. Actions planned by Philips IGT-S (SRN: NL-MF-000001489) to correct the problem

Philips will be disabling SmartPerfusion and 2D Perfusion from use. A Philips representative will be contacting you to schedule an appointment to disable the software (Ref: FCO72200524).

This notice has been reported to the appropriate Regulatory agencies.

Philips regrets any inconvenience caused by this matter. Please be assured that maintaining a high level of safety and quality is our highest priority. If you need any further information or support concerning this matter, please contact your local Philips representative.

Sincerely,

...
URGENT Field Safety Notice Response Form

Reference: IGT-S FCO72200524
SmartPerfusion and 2d Perfusion May Inaccurately Present Time Density Curves and Images

Instructions: Please complete and return this form to Philips promptly and no later than 30 days from receipt. Completing this form confirms receipt of the Urgent Field Safety Notice, understanding of the issue, and required actions to be taken.

Customer/Consignee/Facility Name: __________________________________________________________

Street Address: _________________________________________________________________________

City/State/ZIP/Country: ___________________________________________________________________

Customer Actions:
• Stop using SmartPerfusion and 20 Perfusion.
• Place this Urgent Field Safety Notice with the documentation of the system.
• Circulate this notice to all users so that they are aware of the product issue.
• Return the attached reply form to Philips to confirm that the users of the system have reviewed and understood this Urgent Field Safety Notice.

We acknowledge receipt and understanding of the accompanying Urgent Field Safety Notice and confirm that the information from this Notice has been properly distributed to all users that handle the SmartPerfusion and/or 2D Perfusion software. We also acknowledge that we are no longer using the SmartPerfusion/2D Perfusion software as instructed in this communication.

Name of person completing this form:

Signature: ______________________________________________________________________________

Printed Name: __________________________________________________________________________

Title: __________________________________________________________________________________

Telephone Number: _______________________________________________________________________

mail Address: ___________________________________________________________________________

Date (DD /MMM/ YYYY): ____________________________________________________________________

It is important that your organization acknowledges receipt of this letter. Your organization's reply is the evidence required to monitor the progress of this Field Safety Corrective Action.

<provide instructions here or the customer regarding returning the form to Philips, e.g. fax #, email address. For example, "Please fax this completed form to Philips at (xxx)xxx-xxxx" >